QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.35 (-0.71%)
BABA   85.63 (-0.33%)
AMD   97.00 (+1.08%)
T   14.81 (-1.40%)
F   12.28 (-1.21%)
MU   67.07 (-1.28%)
CGC   0.86 (-7.06%)
GE   110.42 (+0.45%)
DIS   79.32 (-0.91%)
AMC   7.65 (-3.29%)
PFE   31.98 (-1.30%)
PYPL   56.77 (-3.67%)
NFLX   376.94 (-0.61%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.35 (-0.71%)
BABA   85.63 (-0.33%)
AMD   97.00 (+1.08%)
T   14.81 (-1.40%)
F   12.28 (-1.21%)
MU   67.07 (-1.28%)
CGC   0.86 (-7.06%)
GE   110.42 (+0.45%)
DIS   79.32 (-0.91%)
AMC   7.65 (-3.29%)
PFE   31.98 (-1.30%)
PYPL   56.77 (-3.67%)
NFLX   376.94 (-0.61%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.35 (-0.71%)
BABA   85.63 (-0.33%)
AMD   97.00 (+1.08%)
T   14.81 (-1.40%)
F   12.28 (-1.21%)
MU   67.07 (-1.28%)
CGC   0.86 (-7.06%)
GE   110.42 (+0.45%)
DIS   79.32 (-0.91%)
AMC   7.65 (-3.29%)
PFE   31.98 (-1.30%)
PYPL   56.77 (-3.67%)
NFLX   376.94 (-0.61%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.35 (-0.71%)
BABA   85.63 (-0.33%)
AMD   97.00 (+1.08%)
T   14.81 (-1.40%)
F   12.28 (-1.21%)
MU   67.07 (-1.28%)
CGC   0.86 (-7.06%)
GE   110.42 (+0.45%)
DIS   79.32 (-0.91%)
AMC   7.65 (-3.29%)
PFE   31.98 (-1.30%)
PYPL   56.77 (-3.67%)
NFLX   376.94 (-0.61%)

Prelude Therapeutics (PRLD) Stock Forecast, Price & News

$2.90
+0.16 (+5.84%)
(As of 01:50 PM ET)
Compare
Today's Range
$2.74
$2.92
50-Day Range
$2.74
$4.79
52-Week Range
$2.65
$8.66
Volume
397,035 shs
Average Volume
100,396 shs
Market Capitalization
$158.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

Prelude Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
227.6% Upside
$9.50 Price Target
Short Interest
Bearish
6.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.36) to ($2.14) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

646th out of 963 stocks

Pharmaceutical Preparations Industry

291st out of 451 stocks


PRLD stock logo

About Prelude Therapeutics (NASDAQ:PRLD) Stock

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma. The company is also developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 2 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

PRLD Price History

PRLD Stock News Headlines

The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
8-K: Prelude Therapeutics Inc
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
The 7 Worst Stocks to Buy Now
Prelude Therapeutics GAAP EPS of $2.44
See More Headlines
Receive PRLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRLD Company Calendar

Last Earnings
8/03/2023
Today
9/27/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRLD
Fax
N/A
Employees
122
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.50
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+227.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-115,440,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.09 per share

Miscellaneous

Free Float
11,214,000
Market Cap
$158.95 million
Optionable
Not Optionable
Beta
0.33
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Krishna Vaddi D.V.M. (Age 57)
    Ph.D., Founder, CEO & Director
    Comp: $805.91k
  • Dr. Edna Huang M.D. (Age 50)
    Pres & Chief Medical Officer
    Comp: $563.55k
  • Dr. Peggy A. Scherle Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $868.62k
  • Mr. Laurent Chardonnet M.B.A. (Age 58)
    Chief Financial Officer
  • Ms. Aimee Crombie Ph.D.
    Sr. VP and Head of Strategic Planning & Operations
  • Dr. Madhu Pudipeddi Ph.D.
    Sr. VP of Technical Operations
  • Lindsey Trickett
    VP of Investor Relations
  • Mr. Bryant David Lim J.D. (Age 52)
    Chief Legal Officer & Corp. Sec.
  • Ms. Michele Porreca M.B.A.
    Chief People Officer
  • Dr. Andrew P. Combs Ph.D. (Age 57)
    Exec. VP & Head of Chemistry













PRLD Stock - Frequently Asked Questions

Should I buy or sell Prelude Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prelude Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" PRLD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRLD, but not buy additional shares or sell existing shares.
View PRLD analyst ratings
or view top-rated stocks.

What is Prelude Therapeutics' stock price forecast for 2023?

4 equities research analysts have issued 12 month price objectives for Prelude Therapeutics' stock. Their PRLD share price forecasts range from $5.00 to $17.00. On average, they expect the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 227.6% from the stock's current price.
View analysts price targets for PRLD
or view top-rated stocks among Wall Street analysts.

How have PRLD shares performed in 2023?

Prelude Therapeutics' stock was trading at $6.04 on January 1st, 2023. Since then, PRLD stock has decreased by 52.0% and is now trading at $2.90.
View the best growth stocks for 2023 here
.

When is Prelude Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our PRLD earnings forecast
.

How were Prelude Therapeutics' earnings last quarter?

Prelude Therapeutics Incorporated (NASDAQ:PRLD) announced its earnings results on Thursday, August, 3rd. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.11.

When did Prelude Therapeutics IPO?

(PRLD) raised $149 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities acted as the underwriters for the IPO.

What is Prelude Therapeutics' stock symbol?

Prelude Therapeutics trades on the NASDAQ under the ticker symbol "PRLD."

Who are Prelude Therapeutics' major shareholders?

Prelude Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Boxer Capital LLC (4.55%), BlackRock Inc. (1.57%), Woodline Partners LP (0.45%), Geode Capital Management LLC (0.44%), State Street Corp (0.34%) and Renaissance Technologies LLC (0.33%). Insiders that own company stock include Andrew Combs, Brian Piper, Christopher Pierce, David J Mauro, David J Mauro, Deborah Morosini, Jane Huang, Krishna Vaddi, Laurent Chardonnet, Orbimed Advisors Llc and Peggy Scherle.
View institutional ownership trends
.

How do I buy shares of Prelude Therapeutics?

Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prelude Therapeutics' stock price today?

One share of PRLD stock can currently be purchased for approximately $2.90.

How much money does Prelude Therapeutics make?

Prelude Therapeutics (NASDAQ:PRLD) has a market capitalization of $158.95 million. The company earns $-115,440,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis.

How many employees does Prelude Therapeutics have?

The company employs 122 workers across the globe.

How can I contact Prelude Therapeutics?

The official website for the company is www.preludetx.com. The company can be reached via phone at 302-467-1280 or via email at prelude@argotpartners.com.

This page (NASDAQ:PRLD) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -